Bracco International Bv

Bracco Imaging S.p.a.

Bracco Research, USA

Other

E. R. Squibb Sons, Inc.

Ohio State Innovation Foundation

Bracco Diagnostics Inc.

Bracco Suisse Sa

Bristol-myers Squibb

Tweedle, Michael F.

Nunn, Adrian D.

Strauss, Harry W.

Michael F Tweedle

Karen E Linder

Edmund R Marinelli

Natarajan Raju

Kondareddiar Ramalingam

Adrian D Nunn

Palaniappa Nanjappan

Ramachandran S Ranganathan

Rolf E Swenson

Luciano Lattuada

Radhakrishna K Pillai

Enrico Cappelletti

Thangavel Arunachalam

Paul W Wedeking

Glen T Gaughan

Mathew A Von Wronski

James J Hagan

Michel Schneider

Feng Yan

Ruth Wager

Rama S Ranganathan

Ruth E Wager

Jean F Desreux

Helen Fan

Harry W Strauss

Sang I Kang

Li Gong

Peter C Ratsep

Shankaran Kothandaraman

Lon J Wilson

Hong (Helen) Fan

Krishan Kumar

Mary Ellen Maddalena

Valerie Humblet

Vincent Jacques

Martine Hermann

Vinciane Comblin-Tholet

Daniel W Lee

Joseph E Bradshaw

Thomas R Wagler

James T Hagan

Nataranjan Raju

C Allen Chang

Chadwick Lewis Wright

Rajesh Shukla

Xun Zhang

Radhakrishna Pillai

Disclosed are anti-TAG-72 imaging agents and methods of their use.

3E8.scFv.Cys-IR800 conjugate targeting TAG-72 in an orthotopic colorectal cancer model

Disclosed are compositions and methods relating to novel tumor targeting peptides.

Peptide-based cancer imaging agents

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N&#x2014;O&#x2014;P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N&#x2014;O&#x2014;P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Gastrin releasing peptide compounds

Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer, said methods comprising the step of administering to a subject a dose comprising an amount of radioactively labeled L70, N-[4-[[[[[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]acetyl]amino]benzoyl]-L-glutaminyl-L-tryptophyl-L-alanyl-L-valyl-glycyl-L-histidyl-L-leucyl-L-methioninamide. 

Improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N&#x2014;O&#x2014;P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N&#x2014;O&#x2014;P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.

The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

Compounds for targeting endothelial cells, compositions containing the same and methods for their use

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N&#x2014;O&#x2014;P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are define herein (in the form complexed with a metal radionuclide or not), N&#x2014;O&#x2014;P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

New and improved compounds for use in diagnostic imaging or therapy having the formula M&#x2014;N&#x2014;O&#x2014;P&#x2014;G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N&#x2014;O&#x2014;P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.

Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic applications

Diagnostic and therapeutic compositions in the form of complexes for enhancing transmembrane transport of a diagnostic or therapeutic agent and methods for their use. The complexes contain the &#x3b1;, &#x3b3;, or bis isomers of folate receptor-binding analogs of folate, a metal chelated by a ligand, and in one embodiment, a chemotherapeutic agent.

Metal complexes derivatized with folate for use in diagnostic and therapeutic applications

Growing community of inventors

Princeton, NJ, United States of America

Michael F Tweedle